BioSyent Inc. (CVE:RX – Get Free Report) passed above its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of C$14.36 and traded as high as C$15.50. BioSyent shares last traded at C$15.49, with a volume of 416 shares.
BioSyent Trading Down 0.1%
The stock has a market cap of C$175.53 million, a PE ratio of 19.76 and a beta of 1.00. The company has a quick ratio of 6.91, a current ratio of 1.89 and a debt-to-equity ratio of 11.66. The stock’s fifty day moving average price is C$14.36 and its 200 day moving average price is C$14.49.
Insider Transactions at BioSyent
In related news, Director Seyed Ahmad Ashrafi sold 1,884 shares of the company’s stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of C$14.65, for a total value of C$27,600.60. Following the transaction, the director directly owned 37,261 shares of the company’s stock, valued at approximately C$545,873.65. This represents a 4.81% decrease in their position. Over the last quarter, insiders sold 4,358 shares of company stock valued at $63,132. Corporate insiders own 33.65% of the company’s stock.
BioSyent Company Profile
BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis.
Further Reading
- Five stocks we like better than BioSyent
- Sandisk Just Delivered a Blowout Quarter—Here’s Why the Stock Is Falling
- 4 Oil and Gas ETF Plays as Prices Stay Sky-High
- What Tesla Stands to Lose If It Walks Away From China
- Disney Sets Up for a Magical Year in 2027
Receive News & Ratings for BioSyent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSyent and related companies with MarketBeat.com's FREE daily email newsletter.
